Department of Pharmacy

Permanent URI for this collectionhttp://localhost:4000/handle/123456789/1931

Browse

Filters

2022 - 20243

Settings

Author: search.filters.author.Pandey, Murali MonoharSubject: search.filters.subject.Nanocarriers

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Nanoparticle-based materials for wound management
    (Elsevier, 2024) Pandey, Murali Monohar
    Nanotechnology is an approach where nanoscale materials are biomedically used for the prevention of various diseases and infections. Their smaller size and larger surface area make them appropriate for various applications. Nanomaterials have immense potential for being used intrinsically or as nanocarriers to accelerate the process of wound healing and prevent any further bacterial contamination. In recent decades, research on nano-based therapies has reduced the incidence of acute and chronic infections which may lead to life-threatening situations if left untreated. Nanomaterials exist in various forms and structures such as nanospheres, nanocolloids, nanoemulsions, nanocapsules, and nanocarriers, which can be fabricated using different technologies such as electrospinning and further could be potentially used as antimicrobial agents. In this chapter, we have demonstrated the advantages of using nanoparticles combined with traditional methodologies. Besides, we have elucidated the innovative strategies which use nanomaterials as either organic or inorganic nanoparticles. Further in-depth analytical reviews and future clinical experiments are necessarily required because existing wound healing therapies are not sufficient to provide excellent outcomes.
  • No Thumbnail Available
    Item
    Engineering of structural and functional properties of nanotherapeutics and nanodiagnostics for intranasal brain targeting in Alzheimer's
    (Elsevier, 2022-03) Pandey, Murali Monohar
    Alzheimer's disease (AD) is the fifth leading cause of death on the planet. It hallmarks the presence of amyloid plaques and neurofibrillary tangles in geriatric patients. The condition witnesses early stages of mild dementia and learning inabilities. It progressively culminates into impaired behavioural functions, cognitive inability and impaired memory functions. Also, the COVID-19 pandemic has raised new concerns for AD patients as they are at higher risk of infection with COVID-19 than non-AD patients. The increasing toll of Alzheimer's patients is alarming a need for effective and safe therapeutics. This review discusses the various nanocarriers in delivering therapeutics for Alzheimer's via the intranasal route. Nanocarrier based therapeutic, diagnostic and theragnostic applications concerning AD have been covered. The review also discusses the nasal transport pathways and nanocarrier characteristics' role in cellular uptake mechanism. We have briefly discussed the potential biomarkers, imaging modalities, nano vaccines, advanced theragnostic probes, and related clinical studies. Lastly, we discussed the prospects concerning the development of intranasal nanodiagnostics and nanotherapeutics in Alzheimer's. Overall, this review summarizes various intranasal brain targeting strategies in AD.
  • No Thumbnail Available
    Item
    Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease
    (Elsevier, 2023-06) Pandey, Murali Monohar
    Parkinson's disease (PD) is the second leading neurodegenerative disease globally, impacting the quality of life of millions of people. It is estimated that the treatment cost of PD in the USA can rise to 79 billion dollars by 2037. Limited drugs are approved by USFDA, which only provides symptomatic relief. Further, the drug efficacy is challenged due to low drug-brain concentration due to first-pass metabolism and blood-brain barrier (BBB). Intranasal drug administration can offer several advantages over systemic administration, providing efficient brain delivery. Nose-to-brain (N2B) drug delivery can enhance brain bioavailability, reduce enzymatic degradation, and reduce systemic adverse effects. However, due to poor absorption from the nasal mucosa, intranasal administration can be challenging for hydrophilic drugs. The drug mucociliary clearance, retention time, and nasal enzymatic degradation can also affect N2B drug delivery. Nanocarriers can enhance residence time, improve nasal permeation, increase brain uptake, and reduce enzymatic degradation. This review discusses the roles and applications of various N2B nanocarriers to treat PD effectively. Clinical trials of antiparkinson molecules is also covered. Lastly, safety aspects and prospects of potential nanotherapeutics for the effective treatment of PD are discussed.